Amanote Research
Register
Sign In
Promotion of PDT Efficacy by a BCL-2 Antagonist
Photochemistry and Photobiology
- United States
doi 10.1111/j.1751-1097.2007.00267.x
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Theoretical Chemistry
Radiation
Biochemistry
Physical
Date
May 1, 2008
Authors
David Kessel
Publisher
Wiley
Related search
Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
ABT-737, a Small Molecule BCL-2/BCL-xL Antagonist, Increases Antimitotic-Mediated Apoptosis in Human Prostate Cancer Cells
PeerJ
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
Neuroscience
A Phase I Study of Obatoclax Mesylate, a BCL-2 Antagonist, Plus Topotecan in Solid Tumor Malignancies
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Downregulation of BCL-2 Expression in Lymphoma Cells by BCL-2 ARE-targeted Modified, Synthetic Ribozyme
Cancer Gene Therapy
Cancer Research
Molecular Medicine
Molecular Biology
Inhibition of Fas-Induced Apoptosis by BCL-2
Oncogene
Cancer Research
Genetics
Molecular Biology
Downregulation of Autophagy by Herpesvirus BCL-2 Homologs
Autophagy
Cell Biology
Molecular Biology
Synergistic BCL-2 Inhibition by ABT-737 and Cyclosporine A
Apoptosis : an international journal on programmed cell death
Cell Biology
Pharmacology
Biochemistry
Clinical Biochemistry
Cancer Research
Pharmaceutical Science
2-Deoxyglucose-Induced Toxicity Is Regulated by BCL-2 Family Members and Is Enhanced by Antagonizing BCL-2 in Lymphoma Cell Lines
Oncogene
Cancer Research
Genetics
Molecular Biology
WL-276, an Antagonist Against BCL-2 Proteins, Overcomes Drug Resistance and Suppresses Prostate Tumor Growth
Cancer Research
Cancer Research
Oncology
